Drug Profile

CB 2782

Alternative Names: Anti-complement Factor 3 (C3) pegylated CB 2782; CB 2782-PEG; CB-2782; IVT CB 2782-PEG

Latest Information Update: 01 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Catalyst Biosciences
Developer Gyre Therapeutics
Class Eye disorder therapies; Peptide hydrolases
Mechanism of Action Complement C3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Dry age-related macular degeneration

Most Recent Events

30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
26 May 2022 Catalyst Biosciences has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals
15 Mar 2022 Preclinical development in Dry age-related macular degeneration is ongoing in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com